Cardiovascular and Renal Outcomes Trials - Is There a Difference?

American Journal of Cardiology

Volumn 116, Issue 6, 2015, Pages 982-988

  Raggi, Paolo ^a   Boer, Robert ^b   Goodman, William G ^c   Kalantar Zadeh, Kamyar ^d   Chertow, Glenn M ^e   Belozeroff, Vasily ^f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Health Economics and Epidemiology   (United States)

^c Fontana Medical Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIBLIOGRAPHIC DATABASE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; POPULATION; PRIORITY JOURNAL; SHORT COURSE THERAPY; CARDIOVASCULAR DISEASES; COMPLICATION; KIDNEY FAILURE, CHRONIC; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR AGENT;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RESEARCH DESIGN;

EID: 84940586102     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.06.024     Document Type: Review

References (48)

1. U.S. Renal Data System USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [Internet] 2013 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD Available at: http://www.usrds.org/atlas13.aspx Accessed on December 12, 2014
2. C. Wanner, V. Krane, W. März, M. Olschewski, J.F. Mann, G. Ruf, E. Ritz German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
3. EVOLVE Trial Investigators G.M. Chertow, G.A. Block, R. Correa-Rotter, T.B. Drüeke, J. Floege, W.G. Goodman, C.A. Herzog, Y. Kubo, G.M. London, K.W. Mahaffey, T.C.H. Mix, S.M. Moe, M.-L. Trotman, D.C. Wheeler, and P.S. Parfrey Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis N Engl J Med 367 2012 2482 2494
4. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, D.M. Okamoto, S.J. Schwab, and D.A. Goodkin The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
5. R. Wilson, P. Zhang, M. Smyth, and R. Pratt Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy Curr Med Res Opin 25 2009 3021 3028
6. B.C. Fellström, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, J. Beutler, D.-W. Chae, A. Chevaile, S.M. Cobbe, C. Grönhagen-Riska, J.J. De Lima, R. Lins, G. Mayer, A.W. McMahon, H.-H. Parving, G. Remuzzi, O. Samuelsson, S. Sonkodi, D. Sci, G. Süleymanlar, D. Tsakiris, V. Tesar, V. Todorov, A. Wiecek, R.P. Wüthrich, M. Gottlow, E. Johnsson, F. Zannad AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
7. W.L. St Peter, J. Liu, E. Weinhandl, and Q. Fan A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data Am J Kidney Dis 51 2008 445 454
8. IMS Health - US National Prescription Audit 2013 http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI-US-Use-of-Meds-for-2013.pdf Accessed on April 14, 2015
9. American Heart Association, American Stroke Association. Cardiac Medications [Internet]. Available at: http://www.heart.org/HEARTORG/Conditions/HeartAttack/PreventionTreatmentofHeartAttack/Cardiac-Medications-UCM-303937-Article.jsp. Accessed on December 12, 2014.
10. B. Di Iorio, D. Molony, C. Bell, E. Cucciniello, V. Bellizzi, D. Russo, A. Bellasi INDEPENDENT Study Investigators Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial Am J Kidney Dis 62 2013 771 778
11. G.A. Block, P. Raggi, A. Bellasi, L. Kooienga, and D.M. Spiegel Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients Kidney Int 71 2007 438 441
12. Y. Matsumoto, Y. Mori, S. Kageyama, K. Arihara, T. Sugiyama, H. Ohmura, T. Yakushigawa, H. Sugiyama, Y. Shimada, Y. Nojima, and N. Shio Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients J Am Coll Cardiol 63 2014 528 536
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
14. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group N Engl J Med 321 1989 129 135
15. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group Stroke 24 1993 543 548
16. P.S. Sever, B. Dahlöf, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren ASCOT investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
18. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, K. Luomanmäki, B. Dahlöf, U. de Faire, C. Mörlin, B.E. Karlberg, P.O. Wester, and J.E. Björck Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
19. P.A. Poole-Wilson, K. Swedberg, J.G. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W.J. Remme, C. Torp-Pedersen, A. Scherhag, A. Skene Carvedilol Or Metoprolol European Trial Investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
20. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group JAMA 265 1991 3255 3264
21. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet 348 1996 1329 1339
22. Digitalis Investigation Group A. Ahmed, F. Waagstein, B. Pitt, M. White, F. Zannad, J.B. Young, and S.H. Rahimtoola Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial Am J Cardiol 103 2009 82 87
23. L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjeldsen, L.H. Lindholm, J.O. Syvertsen, J. Lanke, U. de Faire, B. Dahlöf, and B.E. Karlberg Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 356 2000 359 365
24. K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Rydén, and H. Wedel Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med 327 1992 678 684
25. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
26. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, and V. Manninen Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
27. J.N. Cohn, D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, W.B. Dunkman, W. Jacobs, G.S. Francis, and K.H. Flohr Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N Engl J Med 314 1986 1547 1552
28. A. Amery, W. Birkenhäger, P. Brixko, C. Bulpitt, D. Clement, M. Deruyttere, A. De Schaepdryver, C. Dollery, R. Fagard, and F. Forette Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial Lancet 1 1985 1349 1354
29. ACTIVE I Investigators S. Yusuf, J.S. Healey, J. Pogue, S. Chrolavicius, M. Flather, R.G. Hart, S.H. Hohnloser, C.D. Joyner, M.A. Pfeffer, and S.J. Connolly Irbesartan in patients with atrial fibrillation N Engl J Med 364 2011 928 938
30. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
31. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, R.J. Prineas, and W. Friedewald Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
32. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.-J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, E.M. Antman TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
33. R.P. Byington, B.R. Davis, J.F. Plehn, H.D. White, J. Baker, S.M. Cobbe, and J. Shepherd Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project Circulation 103 2001 387 392
34. B. Pitt, B. O'Neill, R. Feldman, R. Ferrari, L. Schwartz, H. Mudra, T. Bass, C. Pepine, M. Texter, H. Haber, A. Uprichard, L. Cashin-Hemphill, R.S. Lees QUIET Study Group The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Am J Cardiol 87 2001 1058 1063
35. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
36. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, J.J.P. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
37. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
38. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
39. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K.W. Mahaffey, B.M. Scirica, A. Skene, P.G. Steg, R.F. Storey, R.A. Harrington PLATO Investigators A. Freij, and M. Thorsén Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
40. NAVIGATOR Study Group J.J. McMurray, R.R. Holman, S.M. Haffner, M.A. Bethel, B. Holzhauer, T.A. Hua, Y. Belenkov, M. Boolell, J.B. Buse, B.M. Buckley, A.R. Chacra, F.-T. Chiang, B. Charbonnel, C.-C. Chow, M.J. Davies, P. Deedwania, P. Diem, D. Einhorn, V. Fonseca, G.R. Fulcher, Z. Gaciong, S. Gaztambide, T. Giles, E. Horton, H. Ilkova, T. Jenssen, S.E. Kahn, H. Krum, M. Laakso, L.A. Leiter, N.S. Levitt, V. Mareev, F. Martinez, C. Masson, T. Mazzone, E. Meaney, R. Nesto, C. Pan, R. Prager, S.A. Raptis, G.E.H.M. Rutten, H. Sandstroem, F. Schaper, A. Scheen, O. Schmitz, I. Sinay, V. Soska, S. Stender, G. Tamás, G. Tognoni, J. Tuomilehto, A.S. Villamil, J. Vozár, and R.M. Califf Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1477 1490
41. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework Lancet 351 1998 233 241
42. P. Raggi, C. Giachelli, and A. Bellasi Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis Nat Clin Pract Cardiovasc Med 4 2007 26 33
43. K.J. Jager, V.S. Stel, C. Zoccali, C. Wanner, and F.W. Dekker The issue of studying the effect of interventions in renal replacement therapy - to what extent may we be deceived by selection and competing risk? Nephrol Dial Transpl 25 2010 3836 3839
44. B.A. Cooper, P. Branley, L. Bulfone, J.F. Collins, J.C. Craig, M.B. Fraenkel, A. Harris, D.W. Johnson, J. Kesselhut, J.J. Li, G. Luxton, A. Pilmore, D.J. Tiller, D.C. Harris, C.A. Pollock IDEAL Study A randomized, controlled trial of early versus late initiation of dialysis N Engl J Med 363 2010 609 619
45. G. Eknoyan, G.J. Beck, A.K. Cheung, J.T. Daugirdas, T. Greene, J.W. Kusek, M. Allon, J. Bailey, J.A. Delmez, T.A. Depner, J.T. Dwyer, A.S. Levey, N.W. Levin, E. Milford, D.B. Ornt, M.V. Rocco, G. Schulman, S.J. Schwab, B.P. Teehan, R. Toto Hemodialysis (HEMO) Study Group Effect of dialysis dose and membrane flux in maintenance hemodialysis N Engl J Med 347 2002 2010 2019
46. M.P.C. Grooteman, M.A. van den Dorpel, M.L. Bots, E.L. Penne, N.C. van der Weerd, A.H. Mazairac, C.H. den Hoedt, I. van der Tweel, R. Lévesque, M.J. Nubé, P.M. ter Wee, P.J. Blankestijn CONTRAST Investigators Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes J Am Soc Nephrol 23 2012 1087 1096
47. A. Stang, C. Poole, and O. Kuss The ongoing tyranny of statistical significance testing in biomedical research Eur J Epidemiol 25 2010 225 230
48. C.P. Cannon, M.A. Blazing, R.P. Giugliano, A. McCagg, J.A. White, P. Theroux, H. Darius, B.S. Lewis, T.O. Ophuis, J.W. Jukema, G.M. De Ferrari, W. Ruzyllo, P. De Lucca, K. Im, E.A. Bohula, C. Reist, S.D. Wiviott, A.M. Tershakovec, T.A. Musliner, E. Braunwald, R.M. Califf IMPROVE-IT Investigators Ezetimibe added to after acute coronary syndromes N Engl J Med 372 2015 2387 2397